

Apple Health PDL Drug Class Motions

AHDPL Classes

- ▶ Allergy : Antihistamine - Corticosteroids Combinations
- ▶ Antibiotics
 - ▶ Aminoglycosides - Inhaled
 - ▶ Lincosamides - Injectable
 - ▶ Monobactams – Inhaled
 - ▶ Pleuromutilins
- ▶ Anticoagulants : Factor Xa and Thrombin Inhibitors – Oral
- ▶ Bone Density Regulators
 - ▶ Selective Estrogen Receptor Modulators (SERMS)
 - ▶ Sclerostin Inhibitors
- ▶ Cardiovascular Agents : Cardiac Myosin Inhibitors

AHDPL Classes

- ▶ Dermatologics : Macrolide Immunosuppressants
- ▶ Gout Agents : Pegylated Uric Acid Enzymes
- ▶ Neuromuscular Agents : Spinal Muscular Atrophy Agents

AHDPL Classes

Motion: I move that all products in the drug classes listed on slides 2 and 3 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

Antidiabetics

- ▶ Amylin Analogs
- ▶ Anti-CD3 Antibodies
- ▶ DPP4 Inhibitor / SGLT2 Inhibitor Combinations
- ▶ DPP4 Inhibitor / TZD Combinations
- ▶ DPP4 Inhibitors
- ▶ GLP1 Agonist / Insulin Combinations
- ▶ GLP1 Agonists
- ▶ Insulin - Intermediate Acting

Antidiabetics

- ▶ Insulin - Long Acting
- ▶ Insulin - Pre-Mixed
- ▶ Insulin - Rapid Acting
- ▶ Insulin - Short Acting
- ▶ SGLT2 Inhibitors

Antidiabetics

Motion: I move that all products in the drug classes listed on slides 5 and 6 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- At least one GLP-1 receptor agonist with proven cardiovascular benefit administered once weekly shall be preferred on the AHPDL.

- ▶ **Motion: Taylor**
- ▶ **2nd: Davydow**
- ▶ **Abstain: Barkett**

Antihemophilic Products : Gene Therapy Agents

▶ **Motion:** I move that all products in the Antihemophilic Products : Gene Therapy Agents class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: NOT REVIEWED**

▶ **2nd:**

Antipsychotics / Antimanic Agents :

Antipsychotics - Alpha Agonists

- ▶ **Motion:** I move that all products in the Antipsychotics / Antimanic Agents : Antipsychotics - Alpha Agonists class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

Sleep Disorder Agents

- ▶ Non-Benzodiazepine
- ▶ Orexin Receptor Antagonists
- ▶ Selective Melatonin Receptor Agonists
- ▶ Tricyclic Agents

Sleep Disorder Agents

Motion: I move that all products in the drug classes listed on slide 10 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**